The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inducible Clindamycin Resistance in Staphylococci: Should Clinicians and Microbiologists be Concerned?
Abstract
The increasing incidence of a variety of infections due to Staphylococcus aureus--and, especially, the expanding role of community-associated methicillin-resistant S. aureus (MRSA)--has led to emphasis on the need for safe and effective agents to treat both systemic and localized staphylococcal infections. Unlike most previously noted strains of health care-associated MRSA, community-acquired MRSA isolates are often susceptible to several non- beta -lactam drug classes, although they are usually not susceptible to macrolides. Several newer antimicrobial agents and a few older agents are available for treatment of systemic staphylococcal infections, but use may be limited by the relatively high cost of these agents or the need for parenteral administration. Inexpensive oral agents for treatment of localized, community-acquired MRSA infection include clindamycin, trimethoprim-sulfamethoxazole, and newer tetracyclines. Clindamycin has been used successfully to treat pneumonia and soft-tissue and musculoskeletal infections due to MRSA in adults and children. However, concern over the possibility of emergence of clindamycin resistance during therapy has discouraged some clinicians from prescribing that agent. Simple laboratory testing (e.g., the erythromycin-clindamycin "D-zone" test) can separate strains that have the genetic potential (i.e., the presence of erm genes) to become resistant during therapy from strains that are fully susceptible to clindamycin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naimi, T. S. (2003) · JAMA · doi:10.1001/jama.290.22.2976 · Cited by 1,688
Herold, B. C. (1998) · JAMA · doi:10.1001/jama.279.8.593 · Cited by 1,412
Leclercq, R. (2002) · Clinical Infectious Diseases · doi:10.1086/324626 · Cited by 1,102
Erythromycin resistance by ribosome modification
Weisblum, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.577 · Cited by 1,008
Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants
Roberts, M. C., Sutcliffe, J., Courvalin, P., Jensen, L. B., Rood, J., & Seppala, H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2823 · Cited by 874
Stevens, D. L., Gibbons, A. E., Bergstrom, R., & Winn, V. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.1.23 · Cited by 473
Fiebelkorn, K. R., Crawford, S. A., McElmeel, M. L., & Jorgensen, J. H. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4740-4744.2003 · Cited by 454
Self-citationRoss, J. I., Eady, E. A., Cove, J. H., Cunliffe, W. J., Baumberg, S., & Wootton, J. C. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb00696.x · Cited by 358
Siberry, G. K., Tekle, T., Carroll, K., & Dick, J. (2003) · Clinical Infectious Diseases · doi:10.1086/377501 · Cited by 343
MARTÍNEZ-AGUILAR, G., HAMMERMAN, W. A., MASON, E. O., & KAPLAN, S. L. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000073163.37519.ee · Cited by 315
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Bacterial Antibiotic Resistance: The Most Critical Pathogens
Mancuso, G., Midiri, A., Gerace, E., & Biondo, C. (2021) · Pathogens · doi:10.3390/pathogens10101310 · Cited by 1,332
King, M. D., Humphrey, B. J., Wang, Y. F., Kourbatova, E. V., Ray, S. M., & Blumberg, H. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00005 · Cited by 776
EUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
Susceptibility Test Methods: Dilution and Disk Diffusion Methods
Jorgensen, J. H., & Turnidge, J. D. (2015) · Manual of Clinical Microbiology · doi:10.1128/9781555817381.ch71 · Cited by 585
Self-citationModes and Modulations of Antibiotic Resistance Gene Expression
Depardieu, F., Podglajen, I., Leclercq, R., Collatz, E., & Courvalin, P. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-06 · Cited by 427
The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310843 · Cited by 426
Bacterial, Fungal, Parasitic, and Viral Myositis
Crum-Cianflone, N. F. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-08 · Cited by 422
Nguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J., Abraham, E., Trzeciak, S., Huang, D. T., Osborn, T., Stevens, D., & Talan, D. A. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.02.015 · Cited by 356
Bastian, S., Veziris, N., Roux, A.-L., Brossier, F., Gaillard, J.-L., Jarlier, V., & Cambau, E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00861-10 · Cited by 333
Woods, C. R., Bradley, J. S., Chatterjee, A., Copley, L. A., Robinson, J., Kronman, M. P., Arrieta, A., Fowler, S. L., Harrison, C., Carrillo-Marquez, M. A., et al. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab027 · Cited by 308
Community-acquired methicillin-resistant Staphylococcus aureus
Elston, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.018 · Cited by 308
Stryjewski, M. E., & Chambers, H. F. (2008) · Clinical Infectious Diseases · doi:10.1086/533593 · Cited by 268
Gorwitz, R. J. (2008) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31815819bb · Cited by 164
Metadata
- Authors
- Lewis, J. S., & Jorgensen, J. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-15
- Volume
- 40
- Issue
- 2
- Pages
- 280-285
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2151023064
- Cited by
- 313
- References
- 21
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.